We market and manufacture a growing portfolio of FDA-approved medicines, including several generic alternatives, in the United States. Our products include both injectable and ophthalmic prescription medicines.

We are a privately held company concentrated on developing and commercializing clinically critical therapies across various dosage forms and parenteral therapeutic categories, including generics and 505(b)(2) drugs.

We have currently filed one generic injectable used in COVID-19 treatment with the FDA and expect a market entry in 6-8 months. We will file our second drug with the FDA in about 8-10 months. We are seeking funding for our third drug, which is an antibiotic injectable.

We can co-license and partner for the product or provide equity in exchange for funding.

Learn More

Sign up for a free membership. Get instant access to thousands of listings. Learn about our membership plans.

Disclaimer: DealStream has not independently verified any of the information in this listing and makes no warranty as to its accuracy or completeness. This listing does not constitute an offer to sell, solicit or make an offer to buy an investment interest. Offers to sell, or the solicitation of offers to buy, any security can only be made through official offering documents, such as a subscription agreement and private placement memorandum.